SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
glucose lowering therapies, with additional benefits of weight loss and blood pressure …
[HTML][HTML] Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations
K Yau, A Dharia, I Alrowiyti, DZI Cherney - Kidney International Reports, 2022 - Elsevier
SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
G Schernthaner, N Shehadeh, AS Ametov… - Cardiovascular …, 2020 - Springer
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
S Shao, QQ Xu, X Yu, R Pan, Y Chen - Pharmacology & therapeutics, 2020 - Elsevier
Abstract Dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4is) are oral anti-diabetic drugs
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …
SGLT2 inhibitors: physiology and pharmacology
EM Wright - Kidney360, 2021 - journals.lww.com
SGLTs are sodium glucose transporters found on the luminal membrane of the proximal
tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each …
tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each …
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
H Liu, VS Sridhar, J Boulet, A Dharia, A Khan… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …
(CKD) and cardiovascular (CV) disease. Until recently, glycemic and BP control were the …
SGLT2 inhibitors: the sweet success for kidneys
A Dharia, A Khan, VS Sridhar… - Annual Review of …, 2023 - annualreviews.org
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …
Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database
H Nagasu, Y Yano, H Kanegae, HJL Heerspink… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …
Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial
OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …
glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post …